High ERCC1 expression is associated with platinum-resistance, but not survival in patients with epithelial ovarian cancer.
High ERCC1 expression is associated with platinum-resistance, but not survival in patients with epithelial ovarian cancer.
复制标题
DOI：
10.3892/ol.2016.4732
复制
发表时间：
2016-08
期刊：
影响因子：
2.9
通讯作者：
Wu Q
中科院分区：
文献类型：
--
作者：
Du P;Wang Y;Chen L;Gan Y;Wu Q
本研究旨在探讨上皮性卵巢癌（EOC）患者切除修复交叉互补组1（ERCC1）表达与铂类化疗临床耐药性或临床特征（包括生存时间）之间的关系。通过免疫组织化学染色测定 92 例 EOC 患者肿瘤标本中的 ERCC1 表达。通过Kaplan-Meier生存分析、Cox回归分析和χ2检验研究ERCC1表达对无进展生存时间（PFS）或总生存时间（OS）的影响及其与铂类化疗临床耐药的关系。在 92 名 EOC 患者中，89.13%（82/92）患有 ERCC1 阳性肿瘤。铂类耐药患者的阳性率显着高于铂类敏感患者（P<0.05）。 ERCC1 高表达患者的 PFS 和中位 OS 分别为 12 个月和 30 个月，ERCC1 低表达患者的 PFS 和中位 OS 分别为 17 个月和 39 个月。然而，高表达组和低表达组之间的PFS（P=0.099）或OS（P=0.103）没有统计学上的显着差异。此外，基于Cox比例风险回归分析发现ERCC1不是影响EOC患者预后的独立因素。这些结果表明，ERCC1高表达与铂类化疗耐药相关，但与生存时间无关，并且ERCC1蛋白表达不是影响EOC患者预后的独立因素或唯一因素。
The present study aimed to investigate the association between excision repair cross-complementation group 1 (ERCC1) expression and clinical resistance to platinum-based chemotherapy or clinical characteristics, including survival time, in patients with epithelial ovarian cancer (EOC). ERCC1 expression was determined by immunohistochemical staining in 92 tumor specimens from patients with EOC. The effect of ERCC1 expression on progression-free survival time (PFS) or overall survival time (OS), and its association with clinical resistance to platinum-based chemotherapy was investigated by Kaplan-Meier survival analysis, Cox regression analysis and the χ2 test. Of 92 patients with EOC, 89.13% (82/92) had ERCC1-positive tumors. The positive rate was significantly higher in platinum-resistant patients compared with those who were platinum-responding (P<0.05). The PFS and median OS were 12 and 30 months, respectively, in ERCC1 high expression patients, and 17 and 39 months, respectively, in ERCC1 low expression patients. However, there was no statistically significant difference in PFS (P=0.099) or OS (P=0.103) between the high and low expression groups. Furthermore, it was identified that ERCC1 was not an independent factor affecting the prognosis of patients with EOC based on Cox proportional hazards regression analysis. These results demonstrate that high ERCC1 expression is associated with resistance to platinum-based chemotherapy, but not with survival time, and ERCC1 protein expression is not an independent factor or the only factor affecting the prognosis of patients with EOC.